Publication Name	World Journal of Clinical Oncology
Manuscript ID	27858
Country	Netherlands

Received	2016-06-20 09:29
Peer-Review Started	2016-06-20 14:26
To Make the First Decision	2016-08-05 15:20
Return for Revision	2016-08-11 15:04
Revised	2016-08-12 20:28
Second Decision	2016-10-14 14:22
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-10-27 17:20
Articles in Press	2016-10-27 17:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-11-25 13:45
Publish the Manuscript Online	2016-11-29 16:28

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Basic Study
Article Title	Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer
Manuscript Source	Invited Manuscript
All Author List	Nele Van Der Steen, Christophe Deben, Vanessa Deschoolmeester, An Wouters, Filip Lardon, Christian Rolfo, Paul Germonpré, Elisa Giovannetti, Godefridus J Peters and Patrick Pauwels
Funding Agency and Grant Number	Funding Agency Grant Number Institute for Innovation, Science and Technology Flanders 121114
Corresponding Author	Elisa Giovannetti, MD, Department of Medical Oncology, VU University Medical Center, room 1.53, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. elisa.giovannetti@gmail.com
Key Words	Non-small cell lung cancer; Combination therapy; Cisplatin; Crizotinib; cMET
Core Tip	Targeted therapies are a valuable treatment option in non-small cell lung cancer. Several therapies have now been approved like erlotinib and gefitinib for epidermal growth factor receptor - mutant patients and crizotinib for Anaplastic Lymphoma Kinase-rearranged patients. However, resistance against these therapies eventually occurs. Combination therapy might be able to overcome or delay this resistance. Here we investigate the combination of the cMET inhibitor crizotinib with cisplatin in a panel of non-small cell lung cancer (NSCLC) cell lines with different histological and genetic backgrounds. We show that this leads to strong antagonism in all of the used cell lines. Furthermore we also link these results to the earlier in vitro and clinical results of the combination of erlotinib/gefitinib with cisplatin based chemotherapy in NSCLC.
Publish Date	2016-11-29 16:28
Citation	Van Der Steen N, Deben C, Deschoolmeester V, Wouters A, Lardon F, Rolfo C, Germonpré P, Giovannetti E, Peters GJ, Pauwels P. Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World J Clin Oncol 2016; 7(6): 425-432
URL	http://www.wjgnet.com/2218-4333/full/v7/i6/425.htm
DOI	http://dx.doi.org/10.5306/wjco.v7.i6.425

Full Article (PDF)	WJCO-7-425.pdf
Full Article (Word)	WJCO-7-425.doc
Manuscript File	27858-Review.docx
Answering Reviewers	27858-Answering reviewers.pdf
Audio Core Tip	27858-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	27858-Conflict-of-interest statement.pdf
Copyright License Agreement	27858-Copyright assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	27858-Grant application form(s).pdf
Institutional Review Board Approval Form or Document	27858-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	27858-Language certificate.pdf
Peer-review Report	27858-Peer-review(s).pdf
Scientific Misconduct Check	27858-Scientific misconduct check.pdf
Scientific Editor Work List	27858-Scientific editor work list.pdf